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Abstract 
Endometrial cancer is the fourth most frequent cancer in women in Europe, and as its incidence 
is increasing, prevention strategies gain further pertinence. Risk prediction models can be a 
useful tool for identifying women likely to benefit from targeted prevention measures. On the 
basis of data from 201,811 women (mostly aged 30-65 years) including 855 incident endometrial 
cancer cases from eight countries in the European Prospective Investigation into Cancer and 
Nutrition cohort, a model to predict endometrial cancer (EC) was developed. A step-wise model 
selection process was used to select confirmed predictive epidemiologic risk factors. Piece-wise 
constant hazard rates in 5-year age-intervals were estimated in a cause-specific competing risks 
model, five-fold-cross-validation was applied for internal validation.  
Risk factors included in the risk prediction model were body-mass index (BMI), menopausal 
status, age at menarche and at menopause, oral contraceptive use, overall and by different BMI 
categories and overall duration of use, parity, age at first full-term pregnancy, duration of 
menopausal hormone therapy  and smoking status (specific for pre, peri- and post-menopausal 
women). These variables improved the discriminating capacity to predict risk over 5 years from 
71% for a model based on age alone to 77% (overall C statistic), and the model was well-
calibrated (ratio of expected to observed cases = 0.99).  
Our model could be used for the identification of women at increased risk of EC in Western 
Europe. To achieve an EC-risk model with general validity, a large-scale cohort-consortium 
approach would be needed to assess and adjust for population variation.  
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Introduction 
Endometrial cancer (EC) is the fourth most frequent cancer in women in Europe (1). Most cases 
are diagnosed in older women, often after sixty years of age. Although EC is frequently 
diagnosed at an early stage when the disease is curable, about one fifth of all cases have a poor 
prognosis (1). Well-established risk factors for EC include obesity, use of estrogen-only hormone 
replacement therapy (HRT) and polycystic ovary syndrome, whereas the use of combined 
estrogen-plus-progestin HRT and oral contraceptives (OC) are protective (2-8). As the number 
of women living to an older age is steadily growing, together with the prevalence of obesity and 
sedentary lifestyles, the number of EC cases is also expected to increase in the near future (9). 
In view of these developments, prevention strategies gain further pertinence.  
Information on a woman’s risk of developing EC within the next five years derived from valid risk 
models can help physicians to motivate or proactively propose targeted clinical prevention 
measures such as the preventive use of progestin-based hormonal treatments (10). Risk models 
may help balance expected benefits against possible harms of preventive treatments and can 
also be a useful tool for selecting women who may benefit from screening programs (11, 12).  
Recent investigations based on the prospective EPIC cohort have confirmed associations for 
several risk factors with EC, including reproductive factors (5), use of estrogen-alone vs. 
estrogen-plus-progestin HRT (4), excess body weight (13), physical inactivity (14), and cigarette 
smoking, which may have different effects in pre- and post-menopausal women (15). Taken 
together, these findings from the EPIC cohort led to the development of a risk prediction model 
for EC, combining the predictive capability from all of these risk factors. The availability of full 
prospective cohort data allowed direct estimation of absolute risk levels, and the large cohort 
size and number of incident cases of EC allowed  application of robust methods for model 
building and assessment of  discriminative capacity and calibration of absolute risk estimates. 
 
Methods 
The EPIC cohort 
Study participants and baseline data collection 
The European Prospective Investigation into Cancer and Nutrition (EPIC) is a multicenter, 
population-based cohort study including more than 520,000 participants (367,903 women), 
enrolled into the cohort between 1992 and 2000 in 23 study centers across 10 different countries 
(i.e. Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden and 
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United Kingdom).  The cohort population and data collection procedures have been described in 
detail elsewhere (16). All participating women completed questionnaires on their diet, lifestyle, 
menstrual and reproductive histories, and medical history. All study participants provided written 
informed consent, and the local ethical review boards of the participating institutions gave 
approval for the studies. 
In most countries, height and weight were measured at recruitment according to standardized 
protocols. However, in EPIC-Oxford and approximately two-thirds of the French cohort, height 
and weight were self-reported. Body mass index was calculated as weight (kg) / (height (m))².  
Data from the recruitment questionnaire included age at menarche, age at first and number of 
full-term pregnancies, duration of OC use, and for postmenopausal women additional questions 
addressed age at menopause and past or current HRT use. Women were considered 
premenopausal at baseline, if they reported having had regular menses over the past 12 months 
or if they were less than 46 years of age. Women who reported a bilateral ovariectomy or not 
having had any menses over the last 12 months or who were over 55 years old at recruitment 
were considered postmenopausal. Women between 46 and 55 years of age at recruitment with 
missing or incomplete questionnaire data on menopausal status were classified as peri-
menopausal/unknown. Information on menopausal hormone-use at recruitment was used as 
indicator of ever use and cumulative duration.  
Smoking behavior at baseline was summarized into categories of never, former, current or 
unknown. School level was considered  a proxy for socioeconomic status. Information on self-
reported diabetes, hypertension and hyperlipidemia at baseline was recorded in categories of 
yes, no and unknown. 
Prospective ascertainment of cancer endpoints and vital status. 
Incident cancer cases were identified through several methods, including record linkage with 
regional cancer registries (Denmark, Italy, the Netherlands, Spain and the United Kingdom), 
linkage to health insurance records, active follow-up of study subjects and systematic requests 
of patient records from pathology registries (France, Germany and Greece) (16). Data on vital 
status were obtained from mortality registries at the regional or national level.  
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Statistical Analyses 
Exclusions 
Participants who had reported hysterectomy (N=39,953), a prevalent cancer (except non-
melanoma skin cancer) at the time of recruitment (N=15,317), or with missing follow-up data 
(lost to follow-up immediately after recruitment; N=2,591), were not considered in the  analyses. 
Data from Norway and Sweden  (N=61,119) were excluded, because several risk variables of 
interest had not been collected. Information on incident hysterectomy during follow-up was not 
available for this analysis. Simple imputation of sporadic missing values allowed us to use 
201,811 participants with complete covariate data (81% of all eligible subjects).  
Statistical Model 
To derive an age specific absolute risk score from a number of risk factors we first developed a 
relative risk score. This relative risk score was used to calculate country- and age-specific 
baseline risk of EC. In a competing risk model these estimates were then combined with 
estimates for risk of hysterectomy and of developing other forms of primary cancer or death 
during follow-up, as detailed below. 
Factors previously associated with EC risk in EPIC (4, 5, 13-15) were modeled in a Cox 
proportional hazards model with age as underlying time scale, starting observation at 
recruitment and ending at EC diagnosis or censored at end of follow-up or other event (death, 
other cancer). This analysis was stratifyed by center and age at recruitment in one-year 
increments. All factors previously associated with EC risk and all relevant interactions were 
combined into this model, together with potential confounders: menopausal status, BMI 
(continuous), interaction of BMI with menopausal status, age at first full term pregnancy (FTP) 
(centered at median age 24, nulliparous women coded 0), number of FTP in categories 
nulliparous, one, two, three or more, age at menarche (centered at median age 13), OC use, 
duration of OC use, interaction of OC use with BMI (for interaction regarded in categories 
normal: BMI<25, overweight: 25<=BMI <30 and obese: BMI>30), age at menopause (centered 
at median age 50, pre-/peri-menopausal women coded as 0), HRT use, duration of HRT use, 
interaction of HRT use with BMI (categorical), smoking status and interaction of smoking status 
with menopausal status, alcohol consumption with interaction with menopausal status, diabetes, 
hypertension and hyperlipidemia, physical activity and highest educational level.  
A backwards elimination procedure was implemented, with inclusion criterion set to p=0.1. 
Linear shrinkage based on 100 bootstrap samples was applied to limit over-fitting. The resulting 
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“shrunk” parameter estimates were combined with the individuals’ observed values into a one-
dimensional relative risk score.  
For the estimation of absolute risks of developing EC, the relative risk score was included into 
the estimation of a piece-wise-constant exponential baseline hazard function (including 
calibration parameters for country of origin), using 5-year age intervals as the underlying time-
scale. Consistently with the Cox model described above, women who died or had another first 
primary incident cancer were censored at their age of that event. From the women’s baseline 
data on prevalent hysterectomy and the age at which hysterectomy had been performed, we 
also estimated age- and country-specific risks of having a hysterectomy. These risk estimates 
were combined into a cause-specific competing risk model (17) for EC risk (probability 𝜋(𝑎, 𝑏, 𝑥), 
i.e. cumulative incidence to develop EC between age a and b with individual risk factor 
combination x) as summarized in formula (1):  
𝜋(𝑎, 𝑏, 𝑥) = 𝐹(𝑎, 𝑏, 𝑥) = ∫ 𝜆1(𝑥) ∙ exp (𝑠 ∙ (−𝜆1(𝑥) − 𝜆2 − 𝜆3𝑏𝑎 )) 𝑑𝑠  (1) 
In this equation 𝜆1(𝑥) = 𝜆1_𝑎 ∙ 𝛽1,𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∙ 𝑟𝑟(𝑥)  represents the cause specific risk of EC 
calculated as product of (piecewise constant) baseline hazard 𝜆1_𝑎 in age-interval 𝑎, the constant 
factor 𝛽1,𝑐𝑐𝑐𝑐𝑐𝑐𝑐 to account for differences in incidence rates between countries, and the relative 
risk score derived from the Cox-model as 𝑟𝑟(𝑥) = exp (𝛽𝑐𝑐′𝑥) . The (piecewise constant) 
competing hazards for death or other cancer 𝜆2 = 𝜆2_𝑎 ∙ 𝛽2,𝑐𝑐𝑐𝑐𝑐𝑐𝑐  and for hysterectomy 𝜆3 =
𝜆3,𝑎,𝑐𝑐𝑐𝑐𝑐𝑐𝑐 were computed without further covariates.   
Absolute risk estimates over 5 years were calculated for each woman, based on her age and 
exposure profile at entry and on the estimates from the relative risk model and the age- and 
country-specific hazards model. Software written in SAS to compute absolute risk estimates for 
any age, projection length, and combination of risk factors is available for download as online 
resource. 
 
Assessment of model quality 
Five-fold cross-validation was applied to our modeling processes to obtain unbiased results on 
model quality on data portions that had been kept aside from model building steps. 
Discriminative quality was evaluated with an extension of the area under the ROC-curve statistic 
(AUROC), the concordance statistic ‘Overall C’ (18). The integrated discrimination improvement 
(IDI) index (19) was used to examine the improvement in discrimination between the  
epidemiologic risk model and a model based on age and country alone. Calibration of absolute 
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risk estimates was assessed as the ratio of expected to observed cases overall. The Hosmer-
Lemeshow test  (20) was used to evaluate model calibration over deciles of the risk score. All 
these analyses were stratified by country, and all were generated using SAS (9.3) software.  
 
Results 
The distribution of the risk factors in the study data and characteristics of incident cases of EC 
are presented in Table 1. The women’s median age at recruitment was 50 years (95% were 
between age 27 and 68). The median follow-up of the study was 11.7 years (range: <1 - 16 
years), and 855 incident cases of EC were diagnosed at median age at diagnosis of 61 years 
(2.5th-97.5th range: 46 – 76 years). Other incident cancers were diagnosed in 11,384 women, 
and 5,142 women died without developing cancer. At recruitment the women’s BMI was on 
average 24 kg/m2. Forty-five per cent (45%) of the women were premenopausal, 39% were 
postmenopausal at baseline. For postmenopausal women the median age at menopause was 
50 years. The majority (59%) of women had used oral contraceptives (OC), and about 14%  
were former or  current HRT users, 2% reported that they had diabetes, 17% hypertension and 
13% hyperlipidemia. Eighteen percent were current smokers, 21% were former smokers and 
60% had never smoked.  
After backwards elimination, the following variables were selected into the prediction model: BMI 
(continuous), age at menopause and duration of HRT-use, each increasing the risk with 
increasing values; age at menarche, duration of OC use (years) by BMI category of lean (BMI < 
25), overweight (BMI 25-30) or obese women (BMI>30), parity, age at first full term pregnancy, 
each decreasing the risk with increasing values, menopausal status and smoking status 
(smoking reduced risk among postmenopausal women). Hazard ratios (HR) are presented in 
Table 2. Overall, there was a five-fold difference in relative risk between the women in highest 
and lowest quintiles of the age-adjusted relative risk score (95%-CI: 3.86-6.56).    
In terms of absolute risk estimates, Figure 1 shows the age-specific percentiles of estimated 
five-year risk of EC. The 80th percentile of the women’s five-year probability of developing EC 
varied from 0.23% at age 50-55 to 0.46% at age 65-70, and for women within the lowest 20% of 
risk the corresponding age-specific five-year probabilities were below 0.07% and 0.11%, 
respectively. For women with the worst risk score (i.e. highest BMI category, early age at first 
period, no OC-use, nulliparous, using HRT for 13 years and a non-smoker) the predicted five-
year risk is 1.6% at age 50 and 4.2% at age 65. The full relative risk score based on the 
coefficients indicated in Table 2 is in the Appendix. 
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A risk model based on age as the only predictor showed a C-statistic of 71% (95%CI: 64-77%). 
The full epidemiologic risk model showed a C-statistic of 77% (95%CI: 68-85%), and provided a 
significantly better overall discrimination than the model based on age only, as indicated by an 
integrated discrimination improvement (IDI) index of 0.18% (95%CI:0.04-0.3%).  
The absolute risk model predicted a total of 313 EC cases to occur in our cohort within five years 
after recruitment whereas 317 were observed during that time (expected-to-observed [E/O] ratio 
of 0.99). The Hosmer-Lemeshaw test showed no significant deviation from the null hypothesis of 
good model fit (p= 0.08). Plots of observed vs. predicted risk by age and by country showed 
generally good internal calibration (Figure 2). Moreover, in each country the observed and 
predicted risk estimates from our cohort data showed a fair degree of concordance with age-
specific incidence rates from regional cancer registries (21) (Figure 2). 
 
Discussion 
We developed an epidemiologic risk model for the prediction of women’s individual probabilities 
of developing EC within a Western European population. Overall, our model provides significant 
discrimination between groups of women at high and low risk to develop EC, and its overall 
discrimination capacity (C-statistic) of about 77% is better than what is currently reported for 
prediction models of breast cancer (53-66%) (22, 23). Although a large part of the overall 
discrimination capacity is based on a woman’s age (C= 71%), the information on the selected 
risk factors of BMI, reproductive history and exogenous hormone use does provide substantial 
improvement to the prediction of EC risk.  
Only one other epidemiologic model for the prediction of absolute risk of EC has recently been 
developed by Pfeiffer et al. (24), using data from three large prospective cohort studies in the 
US. The risk factors in that model largely overlap with ours, although some differences also 
exist. Because our cohort includes a considerable proportion of younger women we could derive 
risk estimates for women from the age of 40. Our selected model also included interaction terms 
of BMI with OC use, and of smoking with menopausal status. Comparing Pfeiffer’s model with 
ours on the eligible part (in terms of age-range and concurring variable definition) of EPIC cohort 
data resulted in an overall C-statistic of 66.8% (95%-CI: 63.5-70.2%) and 69.9% (95%-CI: 61.7-
78.0%) respectively, indicating similar discrimination capacity for both models. However, with a 
ratio of expected to observed cases of 2.4, Pfeiffer’s model was poorly calibrated to our cohort 
(on this data subset our model showed an E/O ratio of 0.98). Since that model had been 
developed and validated on US-cohort data, we would expect our model to perform equally 
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poorly on the US populations studied by Pfeiffer et al. The issue of model performance in the 
light of population variation is addressed in greater detail in supplementary materials available 
as online resource. 
An important use of cancer risk prediction models in preventive oncology is the identification of 
high-risk individuals who may benefit from targeted interventions such as chemopreventive 
treatments or screening programs. By focusing these types of intervention on high-risk 
individuals it is often possible to improve the balance between benefits (prevention of cancer; 
improved chances of cure after early detection) and harms (e.g. treatment side-effects; false-
positive screening diagnoses) (11). With regard to EC, one conceivable type of chemopreventive 
treatment is the use of progestins (7, 8, 10) in the form of combined OC (25), or progestin-based 
alternatives such as a depot of medroxyprogesterone acetate (MPA) (26) or a levonorgestrel-
releasing intra-uterine system (LNG-IUS) (27).  
Regarding EC screening, existing modalities include measurement of endometrial thickness by 
trans-vaginal ultrasound sonography (TVS) and concurrent endometrial biopsy (28). Recent 
observational data from a large-scale cohort in the United Kingdom provided some indication of 
the utility of targeted screening high-risk groups (12). Limiting TVS screening to a higher risk 
group selected on the basis of epidemiologic risk factors improved sensitivity and specificity to 
84% and 90% respectively, and calculations showed that 40% of EC cases could have been 
diagnosed by screening only 25% of the population. 
Whereas the prospective cohort design and the large size of the EPIC cohort and EC case 
numbers are major strengths, our study also has potential limitations. First of all, our study 
lacked information on several major risk factors, both at baseline and during prospective follow-
up. This includes information on polycystic ovary syndrome, which among premenopausal 
women is associated with an approximate three to five-fold increase in EC risk before 
menopause (6, 7) and rates of hysterectomy during the follow-up period. Although our absolute 
risk models were adjusted for estimates of age- and country-specific rates of hysterectomy, the 
lack of incident hysterectomy data at the individual level has likely led to some reduction in the 
discriminating capacity of our model.  A second possible limitation of our study is that we did not 
have complete information on the types of HRT used. Furthermore, we had no complete 
information on histological classification of endometrial tumors. Our prediction model likely 
estimates risk predominantly for the development of type-I (endometrioid) tumors, which 
represent about 85% of all EC occurrences.  
External validation of our model on independent data remains open. However, both model 
building and estimation were separated from validation via cross-validation. Our model showed 
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good internal calibration of absolute risk estimates as compared to observed incidence rates 
within the EPIC cohorts. Comparisons of cohort-specific estimates with incidence rates from 
local cancer registries showed modest discrepancies in some of the EPIC countries (Figure 2). 
In a detailed examination of model performance in EPIC subcohorts we have estimated the 
variation of discrimination and calibration in different European populations (online resource). 
We find a strong heterogeneity between populations originating from different countries in crude 
incidence rates and in the country-effects estimated in our parametric model, which are adjusted 
for the EC-risk factors. Thus, a calibrating constant appears to be necessary to achieve good 
model validity for each individual country. External validation in a single external cohort may not 
be sufficient to assess general validity of such an EC-risk model, as can also be seen from the 
results of Pfeiffer’s model applied to our cohorts. Hence we propose that in general the question 
of model calibration may be best assessed by estimating heterogeneity of model performance in 
diverse cohort populations.  
EPIC cohort participants may not perfectly represent the population at large. This does not put 
the validity of our risk model into question, but it does restrict interpretation of our data with 
regard to the exact percentile distribution of women in the general population that may reach 
given absolute risk thresholds. 
This epidemiologic risk model could be extended using information on possible (pre-) clinical 
symptoms, in particular postmenopausal vaginal bleeding symptoms, previous breast cancer 
and tamoxifen use (29), factors that are all likely to further discriminate women by the likelihood 
of developing, or already having EC. Another possible extension is the additional use of serum-
based biomarkers of EC risk, such as endogenous hormones (30, 31) or biomarkers for early 
tumor detection (32).  
As our model seems well calibrated with good discriminative capacity, we propose it could be 
used as first step in a multilevel prevention procedure and thus builds an important resource for 
further research on the prevention of EC in the general population in Western Europe. The 
observed population variation in EC-risk and EC-risk model performance suggests, that a large-
scale world-wide cohort-consortium approach would be needed to assess and adjust for the 
population variation, to achieve an EC-risk model with general validity. 
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Appendix 
 
The relative risk score as part of our model can be derived from the parameter estimates of the 
relative risk estimates (log(RR)) presented in Table 2 with the following formula: 
RR = exp [0.030 x BMI – 0.023 x (age at 1st period – 13) – 0.019  (if lean OC-user)  
– 0.013 (if overweight OC-user) – 0.036  (if obese OC-user) - 0.023 x duration of OC-use (in 
years) – 0.051 (if single parous) – 0.10 (if 2 full-term pregnancies) – 0.22 (if 3 or more full-
term pregnancies) – 0.017 x (age at 1st full-term pregnancy – 24) – 0.088 (if perimeno-
pausal) – 0.20 (if postmenopausal) + 0.029 x (age at menopause – 50) + 0.031 x duration of 
HRT-use (in years) – 0.11 (if premenopausal former smoker) + 0.040 (if premenopausal 
current smoker) – 0.12 (if postmenopausal former smoker) – 0.21 (if postmenopausal 
current smoker) – 0.14 (if perimenopausal former smoker)]. 
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Table 1: Baseline characteristics of cohort subjects included in the present analyses. 
  
 
Total EC-Cases 
Women included in analyses: N 201811 855 
Age at recruitment Median (2.5 -97.5%)  50 ( 27; 68)  55 ( 41; 69) 
Duration of follow-up (years) Median (min - max)  11.68 (  0.01; 16.29)   6.46 (  0.05; 14.03) 
Non-case N (%) 184,430 ( 91%) 
 
  
Other incident cancer N (%) 11,384 (  6%) 
 
  
Death N (%) 5142 (  3%) 
 
  
Age at censoring or diagnosis Median (2.5 -97.5%)  60.92 ( 37.50; 79.26)  61.37 ( 46.38; 76.17) 
BMI  Median (min - max)  24.13 ( 12.97; 74.46)  26.39 ( 15.18; 58.74) 
Age at 1st period Median (min - max)  13 (  8; 20)  13 (  9; 18) 
Ever full-term pregnancy  N (%) 165,859 ( 82%) 714 ( 84%) 
Age at 1st full-term pregnancy Median (min - max)  24 ( 12; 51)  24 ( 15; 40) 
number of children Median (2.5 -97.5%)   2 (  1;  5)   2 (  1;  4) 
Premenopausal N (%) 90,476 ( 45%) 207 ( 24%) 
Perimenopausal N (%) 32,070 ( 16%) 146 ( 17%) 
Postmenopausal N (%) 79,265 ( 39%) 502 ( 59%) 
Age at menopause Median (2.5 -97.5%)  50 ( 40; 57)  51 ( 40; 59) 
Ever used OC  N (%) 119,662 ( 59%) 334 ( 39%) 
  Among users: duration of use (years) Median (min - max)   5 (  0; 25)   2 (  1; 25) 
Ever use of HRT  N (%) 29,232 ( 14%) 213 ( 25%) 
  Among users: duration of use (years) Median (2.5 -97.5%)   1.50 (  0.08; 13)   2.00 (  0.08; 20) 
Prevalent diabetes N (%) 4706 (  2%) 37 (  4%) 
Unknown N (%) 3710 (  2%) 14 (  2%) 
Prevalent hypertension  N (%) 33,372 ( 17%) 217 ( 25%) 
Unknown N (%) 20,452 ( 10%) 133 ( 16%) 
Prevalent hyperlipidemia N (%) 25,833 ( 13%) 139 ( 16%) 
Unknown N (%) 19,896 ( 10%) 126 ( 15%) 
Smoking status                            Never N (%) 120,419 ( 60%) 578 ( 68%) 
Former N (%) 42,352 ( 21%) 153 ( 18%) 
Smoker N (%) 35,920 ( 18%) 113 ( 13%) 
Unknown N (%) 3120 (  2%) 11 (  1%) 
Highest educational level 
   
    
None N (%) 12,662 (  6%) 62 (  7%) 
Primary school completed N (%) 47,851 ( 24%) 262 ( 31%) 
Technical/professional school N (%) 37,184 ( 18%) 156 ( 18%) 
Secondary school N (%) 46,037 ( 23%) 191 ( 22%) 
Longer education (incl. University deg.) N (%) 50,705 ( 25%) 149 ( 17%) 
Not specified N (%) 7372 (  4%) 35 (  4%) 
Alcohol consumption  (g/d) 
   
    
0 N (%) 33,809 ( 17%) 167 ( 20%) 
>0-6 N (%) 83,459 ( 41%) 351 ( 41%) 
>6-12 N (%) 35,000 ( 17%) 147 ( 17%) 
>12-24 N (%) 29,847 ( 15%) 115 ( 13%) 
>24-60 N (%) 18,161 (  9%) 71 (  8%) 
>60-96 N (%) 1387 (  1%) 3 (  0%) 
>96 N (%) 148 (  0%) 1 (  0%) 
Physical activity index  
   
    
Inactive N (%) 49,865 ( 25%) 224 ( 26%) 
Moderately inactive N (%) 71,918 ( 36%) 311 ( 36%) 
Moderately active N (%) 48,844 ( 24%) 183 ( 21%) 
Active N (%) 31,184 ( 15%) 137 ( 16%) 
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Table 2: Multivariate relative risk estimates (adjusted for age and center) for epidemiological 
factors in the risk prediction model (with 95%-confidence interval limits). 
  Relative Risk 
95% confidence 
interval 
BMI  per unit (kg/m²) increase 1.07 (1.06; 1.09) 
Age at 1st period (per year, centered at med. 13) 0.95 (0.91; 0.99) 
   OC-use (ever) in lean women (BMI<25) 0.96 (0.79; 1.16) 
   OC-use (ever) in overweight women (25<BMI<30) 0.74 (0.48; 1.14) 
   OC-use (ever) in obese women (BMI>30) 0.92 (0.57; 1.48) 
Duration of OC-use (per year) 0.95 (0.93; 0.96) 
Parity: nulliparous 1.00 
 
  
one child 0.89 (0.72; 1.10) 
two children 0.80 (0.67; 0.95) 
three or more children 0.60 (0.50; 0.73) 
Age at 1st full term pregn.   
(per year, centered at median 24)         0.96 (0.95; 0.98) 
Premenopausal 1.00 
 
  
Perimenopausal 0.82 (0.63; 1.06) 
Postmenopausal 0.63 (0.48; 0.84) 
Age at menopause  
(per year, centered  at median 50) 1.07 (1.05; 1.09) 
Duration of HRT use (per year) 1.07 (1.06; 1.10) 
Smoking status: never (ref) 1.00 
 
  
Smoking in premenopausal women:   
 
  
former 0.78 (0.56; 1.09) 
Smoker 1.10 (0.80; 1.51) 
unknown 1.45 (0.61; 3.48) 
Smoking in postmenopausal women 
 
  
Former 0.77 (0.38; 1.56) 
Smoker 0.62 (0.30; 1.30) 
Unknown 0.44 (0.04; 4.69) 
Smoking in perimenopausal women 
 
  
Former 0.73 (0.32; 1.68) 
Smoker 1.00 (0.44; 2.27) 
Unknown 1.33 (0.17; 10.23) 
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Figure 1: Age-group-specific 5th, 20th,  50th, 80th and 95th percentiles of estimated 5-year risk of 
developing endometrial cancer in the EPIC-cohort.  
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Figure 2: Country and age-specific annual EC risk as observed and predicted in our cohort, 
compared with rates from registries.  
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Generalizability of model performance  
 
1. Comparison between countries: 
International registry data on endometrial cancer show country-wise differences in (age-specific) 
incidence rates as presented in Figure S1. The overall trend is an increase of risk from the age 
of 48 to its 5-6-fold level between age 60 and 65 and then levelling or slight decline.  
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Figure S1: annual incidence rates of endometrial cancer in Western Europe in 5-year age-groups as 
provided by registries. 
For our model we use age as the underlying time-scale. For derivation of the relative risk score, 
center is used as stratification factor, to account for differences due to study-setup and 
investigator. While it makes sense to rule out inter- and intra-country differences due to different 
study situations in estimating general relative risks, a center-specific differentiation would not 
make sense for estimation and application of absolute risks in a clinical setting. The final model 
includes simple categorical effects (in a proportional parametric survival model) for country to 
allow for variation between populations in terms of average effects. These estimated country-
effects are per construction adjusted for the common effect of the covariates selected into the 
final model and for age – thus, the country-effects describe population specific heterogeneity in 
risks in a uniform manner that is not accounted for by the selected, risk-related covariates. 
These country-related model effects may reflect uncaptured country-specific variation in life-style 
factors such as diet, physical activity, family life or health care provision.   
We estimate the absolute risk as cumulative incidence according to formula 1: 
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π(a, b, x) = F(a, b, x) = � λ1(x) ∙ exp (s ∙ (−λ1(x) − λ2 − λ3b
a
)) ds, 
𝐹(𝑎, 𝑏, 𝑥) = � 𝜆1(𝑥) ∙ exp (𝑠 ∙ (−𝜆1(𝑥) − 𝜆2 − 𝜆3𝑏
𝑎
)) 𝑑𝑠, 
where λ1(x) = λ1_a ∙ β1,country ∙ rr(x) represents the cause specific risk of EC, and is calculated as 
product of (piecewise constant) baseline hazard λ1_a  in age-interval a , a  constant factor 
β1,country to account for differences in incidence rates between countries, and the relative risk 
score derived from the Cox-model as rr(x) = exp (βrr′x). The (piecewise constant) competing 
hazards for death or other cancer enter this calculation as λ2 = λ2_a ∙ β2,country  and for 
hysterectomy λ3 = λ3,a,country.  
The EC-specific component resolves to   
π(a, b, x) = 1 − exp (− exp�log(b − a) − βrr ∙ x − λ1_a − β1,country�)   
With the hazard being h(t) = exp�−βrr ∙ x − λ1_a − β1,country� country-specific hazard ratios can 
be derived as  
HR(t) = h(t|country1)
h(t|country_ref) = exp�−βrr∙x−λ1_a−β1,country1�exp�−βrr∙x−λ1_a−β1,country_ref� = exp (β1,country_ref − β1,country1).  
For this analysis we ignore additional complexities due to competing hazards. For a closer look 
at country-specific rates, we derive estimates as presented in Table S1, comparing average 
incidence rates reported from registries with hazard ratios calculated from our model and from a 
model fit to our data with the same model assumptions, but without the relative risk score, i.e. 
without adjustment for covariates. These estimates should be more comparable to registry rates, 
which are also not adjusted for covariates. Differences between these estimates and registry 
rates may reflect country-specific deviations of our sample from the general population (i.e. 
incomplete representativeness). The order of presentation follows the ranking by age-
standardized incidence rates as reported by EUCAN (1), using Denmark as reference category.  
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Table S1: Registry incidence rates and hazard ratios from our risk model and from a model without the 
common covariate effect. 
 Ranking of registry incidence 
rates  (age stdzd.) 
Model without covariate 
risks, age-standardized 
(p<=0.0001) 
Model including 
covariate risks and age 
(p<=0.0001) 
  IR* 
IR 
relative 
to DK 
HRlow HRatio HRup HRlow HRatio HRup 
1 UK 19.7 1.026 0.741 0.886 1.059 0.787 0.941 1.125 
2 Denmark 19.2 1.000  1.000   1.000  
3 Italy 19.2 1.000 0.902 1.070 1.270 0.798 0.948 1.126 
4 Netherlands 17.7 0.922 0.737 0.897 1.092 1.032 1.259 1.537 
5 Germany 16.9 0.880 0.801 0.989 1.222 0.808 0.998 1.233 
6 Spain 16.3 0.849 0.897 1.079 1.298 0.629 0.757 0.912 
7 France 15.2 0.792 0.442 0.534 0.644 0.475 0.573 0.692 
8 Greece 10 0.521 0.192 0.270 0.381 0.134 0.189 0.266 
* Age Standardised Incidence Rate (European) per 100,000 as of 2012,  
The number of cases per country is limited in our sample, which hampers our estimation power.  
However, we do see a variation between countries,  in line with the variation in national 
incidence rates. Greece has extremely low registry rates and appears as an outlier in our sample 
data. The latter effect may at least in part be ascribed to an ascertainment bias caused by the 
local complex active follow-up scheme. 
2. Discrimination across countries: 
In independent, and in our case neutral selection processes both the Pfeiffer group and we 
selected the same or at least very similar risk factors into the prediction model, and the risk 
factors were assigned similar weights.  
The model provided by Pfeiffer is designed only for women of at least 50 years of age and up to 
a prediction age of 90.  
We provide here also results from a model estimated according to our distributional assumptions 
and including our relative risk score, but without country parameters. Estimates from this model 
should be more in line with those from Pfeiffer’s model, which also includes no country-
component. 
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For our model (in cross-validated data) we find discrimination to differ by country. Because also 
the sample age-range affects discrimination, and age-ranges differ  between countries, we use 
only women who were between 50 and 70 years old at recruitment for a standardized 
comparison of discriminative capacity between countries. 
Table S2: Discrimination in terms of overall C (with 95%-confidence limits) of 5-year risk prediction in 50-
70 year old women in our sample provided by our model and by Pfeiffer’s, and by a model with our 
relative risk score, without a country-effect: 
   full model our model without 
country effect 
Pfeiffer's  model 
 Cases 
in 5 
years 
C Low 
95%ci 
C 
Up 
95%ci 
C  
C Low 
95%ci 
C 
Up 
95%ci 
C 
C Low 
95%ci 
C 
Up 
95%ci 
C 
All across 253 0.683 0.650 0.717 0.653 0.619 0.688 0.670 0.636 0.705 
France 45 0.666 0.590 0.742 0.614 0.532 0.696 0.647 0.563 0.731 
Italy 39 0.631 0.541 0.721 0.627 0.542 0.711 0.639 0.560 0.717 
Spain 24 0.694 0.579 0.809 0.691 0.579 0.804 0.626 0.513 0.739 
UK 31 0.736 0.648 0.824 0.688 0.590 0.786 0.728 0.634 0.821 
The 
Netherlands 
26 0.722 0.626 0.817 0.674 0.566 0.782 0.710 0.601 0.819 
Greece 12 0.692 0.561 0.822 0.628 0.487 0.770 0.587 0.427 0.748 
Germany 26 0.762 0.665 0.860 0.735 0.630 0.840 0.741 0.627 0.855 
Denmark 50 0.658 0.582 0.734 0.632 0.554 0.711 0.680 0.598 0.761 
 
Discrimination is overall similar for Pfeiffer’s model and ours. Both models reveal a varying 
discriminative capacity between countries, even within this constrained age-range. Within 
countries the models’ discriminative capacity appears strongly correlated. .  
Comparison of our two model results demonstrates that the country-component improves the 
discriminative capacity not only between countries, but due to its proportionality on risk also 
within countries. With an increase in C (Delta-C) of 3% this would commonly be considered as 
relevant.  
3. Calibration across countries:  
Pfeiffer’s model was externally calibrated but performed poorly in our sample. However, since 
that model was well calibrated to the (white) US population and performed reasonably well in 
validation in this population, we would assume that our model, which is calibrated towards 
specific Western European countries, would perform equally poorly for the populations studied 
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by Pfeiffer et al. for their model development.  Our own E/O ratios (as calculated from cross-
validation results) also show a certain variation, with best fit for Denmark, the Netherlands, 
Germany  and marked  underestimation for the Italy/Greece sample, which was joined for the 
cross-validation analysis, because of the small size of the greek sample. This underestimation 
may be another result of the biased case-ascertainment in Greece, as mentioned above.  
Table S3: Ratios of expected to observed numbers of cases in countries and overall, together with 95%-
confidence intervals calculated from our final model, our model without country-effects and Pfeiffer’s 
model. 
 
Full model 
Model w/out 
country-effect Pfeiffer's model 
  E/O 
low 
95%
ci 
up 
95%
ci E/O 
low 
95%
ci 
up 
95%
ci E/O 
low 
95%ci 
up 
95%ci 
Denmark 1.01 0.76 1.33 1.38 1.04 1.82 2.14 1.62 2.82 
France 1.06 0.79 1.42 1.52 1.13 2.03 2.29 1.70 3.07 
Italy&Greece 0.79 0.60 1.04 1.76 1.34 2.31 2.97 2.25 3.90 
Spain 0.90 0.60 1.34 1.71 1.15 2.55 3.17 2.13 4.73 
UK 0.91 0.64 1.30 1.45 1.02 2.07 2.11 1.49 3.00 
The 
Netherlands 1.01 0.69 1.49 1.28 0.87 1.88 1.98 1.35 2.91 
Germany 0.99 0.68 1.46 1.22 0.83 1.79 2.11 1.44 3.10 
All 0.95 0.84 1.07 1.49 1.32 1.69 2.41 2.13 2.72 
 
 
With our sample including data from eight different Western European countries, we can have a 
look at the variation of model performance for different populations.  
Overall we find agreement on models’ discriminative capacities, but a vulnerability concerning 
the models’ calibration quality. This makes us wary about the recommendation of the application 
of risk models across populations in general terms.  
We observe a North/South gradient in our country effects across Europe, with an overall 
agreement of expected and observed cases for the UK, Italy, Denmark, Germany, and The 
Netherlands, assigning Spain, France and especially Greece a special status.  
Our final model provides reasonable discrimination and good calibration qualities for all countries 
in our sample.  
4. In conclusion:  
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1. Incidence rates differ between countries both in our sample and according to registry 
rates.  
2. These differences can in part be accounted for by differences in the distribution of 
epidemiological factors (life-style, diet, living-conditions, cultural differences etc.).  
3. However, we still find a significant difference between countries remaining, when we 
estimate country specific absolute risk levels in the presence of our relative risk 
score. 
4. Both calibration and discrimination show heterogeneity between countries. 
5. Addition of a country effect to the model improves discrimination to a degree of 
difference in C (Delta-C) of 3%, which is usually considered as relevant and improves 
calibration (changing E/O from 1.47 overall to 0.97).  
External validation provides no safeguard against miscalibration. Calibration seems to be more 
affected from variation between populations than discrimination. It appears that calibration may 
suffer severely when a model is applied to a new population. From our cross-population 
comparison we also deduce that calibration is an issue, which depends on differences between 
populations in factors which are not covered by model components. With a simple categorical 
effect for country (in our setting of proportional parametric survival models) we allow absolute 
risk levels to be on average different for populations from different countries to capture 
population heterogeneity not accounted for with our risk-factors. This heterogeneity may be 
related for example to diet, life-style, but also to infrastructure (child-care, mobility, diet), or 
health care systems, offering medication and diagnosis according to standards differing by 
country and also by time. Both calibration and discrimination are much improved with this 
country-factor. 
Thus we conclude that for an EC-risk model general validity may be achieved only in a setting 
which provides enough power to consider such population variation. Considering the low 
incidence of this disease, a large-scale world-wide cohort consortium may be necessary to 
gather sufficient data from different populations. As seen by the performance of Pfeiffer’s model, 
external validation on single cohorts provides no safeguard against miscalibration in principle.  
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